PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
Tel:+86--18629577295 Address:Room 1502, Unit 3, Building 2, Nanshan Garden, Guodu Street, Chang 'an District, Xi 'an, Shaanxi Province BPC-157 Lyophilized Peptide Powder | High Purity 99%+ | Manufacturer FOB Price: USD $ 30.0-105.0 High Purity: Ensures superior quality and reliability for various applications
Ans: Vitamin B12 injection, also called cyanocobalamin, is prescribed to address vitamin B12 deficiency in dogs, cats, and livestock
70-18-8 Appearance Solid Molecular Weight 307.32 Formula C 10 H 17 N 3 O 6 S Color White to off-white Synonyms GSH
Sustained efficacy and safety of idebenone in the treatment of Alzheimers disease: Update on a 2-year double-blind multicentre study
